Mirum Pharmaceuticals (MIRM) Assets Average (2019 - 2026)

Mirum Pharmaceuticals' Assets Average history runs 8 years deep, the most recent figure standing at $866.9 million for Q1 2026.

• On a quarterly basis, Assets Average rose 27.39% year-over-year to $866.9 million in Q1 2026; TTM through Mar 2026 was $866.9 million, a 27.39% increase from a year earlier, with the FY2025 full-year figure at $756.8 million, up 14.89% from the prior year.
• Assets Average grew to $866.9 million in Q1 2026 per MIRM's latest filing, from $814.0 million in the prior quarter.
• Across five years, Assets Average topped out at $866.9 million in Q1 2026 and bottomed at $286.4 million in Q1 2022.
• The 5-year median for Assets Average is $649.3 million (2024), against an average of $568.0 million.
• Biggest YoY gain for Assets Average was 89.18% in 2024; the steepest drop was 3.19% in 2024.
• Year by year, Assets Average stood at $358.6 million in 2022, then soared by 80.87% to $648.6 million in 2023, then gained by 3.19% to $669.3 million in 2024, then gained by 21.61% to $814.0 million in 2025, then climbed by 6.5% to $866.9 million in 2026.
• Per Business Quant, the three latest MIRM Assets Average figures stand at $866.9 million (Q1 2026), $814.0 million (Q4 2025), and $755.5 million (Q3 2025).